Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Janus Global Life Sciences Fund Class I (JFNIX)

51.10
Net Asset Value
+0.27%
1 Day
-2.29%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.78%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Performance

1 month+9.99% 3 years+18.49%
3 months+6.79% 5 years+21.70%
1 year-15.14% Since inception+20.41%
Data through --

Peer Comparisonvs. Health

 JFNIXCategory
Performance 5-yr return+21.70%+15.57%
Expense ratio0.78%1.32%
Risk 5 year sharpe ratio1.211.02
Net assets$3.9B$3.2B
Average market cap$18.9B$35.5B
Average P/E22.620.8
Portfolio turnover47%47%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyJanus
Fund manager & tenureAndrew Acker / 9 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment--

Holdings

U.S. stock75.94%
International stock20.91%
Fixed income1.98%
Cash0.91%
Other0.26%
Top 5 Sectors
Portfolio weighting
Healthcare 94.74%
Consumer service 3.23%
Consumer goods 0.79%
Business service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AGN Allergan3.79%
AMGN Amgen3.76%
ABBV AbbVie3.20%
CELG Celgene3.09%
BMY Bristol-Myers Squibb2.72%
BSX Boston Scientific Corp2.72%
AET Aetna2.67%
TEVA Teva Pharmaceutical2.49%
-- 2.46%
UHS Universal Health Services Inc2.38%

Partner Offers